Home>Topics>Stocks>C.R. Bard

C.R. Bard

  1. All
  2. Commentary
  3. Headlines
  1. Fitch Affirms Banco De Costa Rica's IDR at 'BB+'; Outlook Stable

    Headlines

    Thu, 18 Dec 2014

    statement was released by the rating agency) NEW YORK, December 18 (Fitch) Fitch Ratings has affirmed Banco de Costa Rica's ( BCR ) Issuer Default Rating (IDR) at 'BB+' and short term IDR at 'B'. Fitch also affirms BCRs Viability Rating (VR) at

  2. CR Bard is Set to See Growth from its U.S. Lutonix Balloon Launch

    Commentary

    Thu, 23 Oct 2014

    CR Bard reported robust third-quarter results that were generally consistent with our projections. While we have not made any significant

  3. CR Bard Bolsters Narrow Moat With Technology That Appeals to Hospitals Seeking Efficiencies

    Commentary

    Mon, 25 Aug 2014

    We have long appreciated CR Bard 's narrow economic moat and have recently taken another look at the firm's product portfolio and general approach to navigating

  4. Boston Scientific Exceeds Our Expectations in the Second Quarter

    Commentary

    Thu, 24 Jul 2014

    in constant currency, propelled by urology and women's products. Moreover, the electrophysiology business purchased from CR Bard provided a boost by rounding out Boston's portfolio with complementary products. Boston held gross margin steady at 70

  5. CR Bard Sees Boost in First Quarter Thanks to Gore Royalties and Acquisitions

    Commentary

    Tue, 22 Apr 2014

    CR Bard reported first-quarter results that slightly exceeded our expectations, thanks to acquisitions made last year as well as royalty

  6. CR Bard Underlying Business Remains Solid in Fourth Quarter

    Commentary

    Fri, 31 Jan 2014

    CR Bard released solid fourth-quarter performance that generally matched our expectations, and we are leaving our fair value estimate

  7. Our Outlook for Health-Care Stocks

    Headlines

    Tue, 31 Dec 2013

    see China as a strategic priority and invested heavily to put down roots there. On the other hand, Edwards EW and C . R . Bard BCR have invested far less extensively in China and do not seem to view penetration of this market as a corporate priority

  8. CR Bard Reports Strong 3Q and We Plan to Raise our Fair Value Estimate

    Commentary

    Tue, 22 Oct 2013

    CR Bard posted strong third-quarter results that slightly exceeded our expectations. We plan to modestly raise our fair value estimate

  9. New Endo CEO Off to Good Start, but Significant Challenges Remain

    Commentary

    Thu, 5 Sep 2013

    increased its litigation reserve to $216 million to account for the increase, but based on recent settlements of similar cases against competitors such as C . R . Bard , it wouldn't be surprising to see the final expense exceed that amount.

  10. CR Bard to buy Rochester Medical for $262 million

    Headlines

    Wed, 4 Sep 2013

    (Reuters) - Medical device company C . R . Bard Inc said it would buy Rochester Medical Inc, which makes products for urinary retention and incontinence, for about $262 million to boost its presence in...

« Prev123Next »
Content Partners